The estimated Net Worth of Willie L. Jr. Brown is at least $3.26 Millón dollars as of 17 June 2021. Mr. Brown owns over 3,037 units of Global Blood Therapeutics stock worth over $2,689,260 and over the last 9 years he sold GBT stock worth over $0. In addition, he makes $574,495 as Independent Director at Global Blood Therapeutics.
Willie has made over 3 trades of the Global Blood Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,037 units of GBT stock worth $208,004 on 17 June 2021.
The largest trade he's ever made was buying 10,000 units of Global Blood Therapeutics stock on 13 March 2020 worth over $523,700. On average, Willie trades about 1,982 units every 51 days since 2015. As of 17 June 2021 he still owns at least 39,265 units of Global Blood Therapeutics stock.
You can see the complete history of Mr. Brown stock trades at the bottom of the page.
Willie L. Brown Jr serves as Independent Director of the Company. Since January 2004, Mr. Brown has served as an attorney at law representing clients before state and local governments. Prior to that, from January 1996 to January 2004, Mr. Brown served as the 41st mayor of San Francisco. Mr. Brown is a practicing attorney, community leader and well-respected public official who served over 31 years in the California State Assembly, spending more than 14 years as its Speaker, from 1980 to 1995. He currently serves as chairman and chief executive officer of The Willie L. Brown, Jr. Institute on Politics and Public Service, an independent, non-profit organization providing a forum for non-partisan education, debate and discussion of public policy issues. Mr. Brown holds a degree in political science from San Francisco State University and a J.D. from University of California, Hastings College of the Law. He has received over 17 honorary degrees from prestigious institutions throughout his life. Mr. Brown’s qualifications to serve on our Board of Directors include more than 50 years of political, business and non-profit experience.
As the Independent Director of Global Blood Therapeutics, the total compensation of Willie Brown at Global Blood Therapeutics is $574,495. There are 19 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
Willie Brown is 86, he's been the Independent Director of Global Blood Therapeutics since 2015. There are no older and 21 younger executives at Global Blood Therapeutics.
Willie's mailing address filed with the SEC is C/O GLOBAL BLOOD THERAPEUTICS, INC., 181 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... y Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Global Blood Therapeutics executives and other stock owners filed with the SEC include: